Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
11:11am, Saturday, 11'th Nov 2023
NEW YORK , Nov. 11, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
04:22pm, Friday, 03'rd Nov 2023
NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
02:54pm, Wednesday, 25'th Oct 2023
NEW YORK , Oct. 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
02:52pm, Tuesday, 17'th Oct 2023
NEW YORK , Oct. 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
05:40pm, Monday, 09'th Oct 2023
NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. ("Myovant" or the "Company") (NASDAQ: MYOV).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
05:48pm, Friday, 29'th Sep 2023
NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd.
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Thursday, 26'th Jan 2023
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
SHAREHOLDER ALERT: Weiss Law Reminds MYOV, KNBE, LMST, and PEBO Shareholders About Its Ongoing Investigations
01:05am, Tuesday, 01'st Nov 2022
NEW YORK , Nov. 1, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
11:19am, Wednesday, 26'th Oct 2022
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Sumitomo Pharma Is Buying Myovant Sciences (MYOV) For $2.9 Billion
11:29pm, Monday, 24'th Oct 2022
Sumitovant Biopharma recently announced it is buying Myovant Sciences (MYOV) in a $2.9 billion deal. This is why.
Myovant Sciences Cancels Second Quarter Earnings Conference Call
04:30pm, Monday, 24'th Oct 2022
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30,
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
11:23am, Monday, 24'th Oct 2022
Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV ) that they don't already own. Furtherm
Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)
09:36am, Monday, 24'th Oct 2022
Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash.
Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
08:12am, Monday, 24'th Oct 2022
Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd.
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
06:45am, Friday, 14'th Oct 2022
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for
